drugset / Trial / NCT03472313

Assessment of the Biodistribution and Safety of [18F]MNI-958 in Healthy Subjects

NCT03472313

Phase 1 Completed 2 enrolled Invicro
NaSingle-groupOpen-labelOther

Summary

The overall goal of this protocol is to evaluate the biodistribution of \[18F\]MNI-958 also known as APN-0000455 or PM-PBB3, as a tau targeted radiopharmaceutical.

Timeline

Start
2017-11-14
Primary completion
2018-04-20
Completion
2018-04-20

Drugs

EvaluationDrugModalityDoseRoute
Subject [18F]APN-1607 Diagnostic / imaging agent Other

Indications

No indication recorded.